Alpha 2.0
Login Register
» Authors » N Personeni

N Personeni

Explore the profile of N Personeni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 519
Followers 0
Related Specialties
Oncology
Pharmacology
General Surgery
Top 10 Co-Authors
A Santoro
L Rimassa
S Tomatis
E Clerici
M Scorsetti
G DAgostino
A Fogliata
A Tozzi
C Iftode
P Navarria
Published In
Ann Oncol
Eur J Immunol
Br J Cancer
Cancer Biol Ther
Acta Gastroenterol Belg
Affiliations
Soon will be listed here.
Recent Articles
1.
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
Baretti M, Personeni N, Destro A, Santoro A, Rimassa L
Cancer Biol Ther . 2018 Mar; 19(8):659-663. PMID: 29580164
Tumors represent a dynamic system where the genomic plasticity permits to adapt to the perturbation induced by environmental pressures, supporting the importance of longitudinal tumor sampling strategies to deciphering the...
2.
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study
Comito T, Cozzi L, Zerbi A, Franzese C, Clerici E, Tozzi A, et al.
Eur J Surg Oncol . 2017 Jan; 43(4):735-742. PMID: 28131670
Objective: To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery. Methods: A retrospective analysis was performed on...
3.
Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study
Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C, et al.
Technol Cancer Res Treat . 2016 Jun; 16(3):295-301. PMID: 27311310
Purpose: To assess the efficacy of stereotactic body radiotherapy in patients with unresectable locally advanced pancreatic cancer. Materials And Methods: All patients received a prescription dose of 45 Gy in...
4.
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
Santoro A, Gebbia V, Pressiani T, Testa A, Personeni N, Arrivas Bajardi E, et al.
Ann Oncol . 2014 Dec; 26(3):542-7. PMID: 25538178
Background: The management of biliary tract cancers (BTCs) is complex due to limited data on the optimal therapeutic approach. This phase II multicenter study evaluated the efficacy and tolerability of...
5.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
Santoro A, Pressiani T, Citterio G, Donadoni G, Pozzi F, Rimassa L, et al.
Br J Cancer . 2010 Aug; 103(6):837-44. PMID: 20717115
Background: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is...
6.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al.
Ann Oncol . 2007 Nov; 19(3):508-15. PMID: 17998284
Background: KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX). Patients And Methods: We studied the KRAS mutation...
7.
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipies
Hendlisz A, Personeni N, Delaunoit T, Debroux S, Flamen P
Acta Gastroenterol Belg . 2006 May; 69(1):55-8. PMID: 16673565
Colorectal cancer is a severe disease with a significant incidence in Western world. In the course of disease, about 40% of patients will eventually develop metastases to the liver. The...
8.
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells
Carson W, Parihar R, Lindemann M, Personeni N, Dierksheide J, Meropol N, et al.
Eur J Immunol . 2001 Oct; 31(10):3016-25. PMID: 11592078
The Her2/neu (c-erbB-2) oncogene encodes a 185-kDa protein tyrosine kinase which is overexpressed in 20% of breast adenocarcinomas and is recognized by a humanized anti-Her2/neu monoclonal antibody (mAb) (rhu4D5 or...